Table 3.

Treatment-related AEs that occurred in at least 10% of patients.

	Regimen Group, No. (%)
	NIVO1 + IPI3 N = 27	NIVO3 + IPI1 N = 33
Pruritus and/or Rash	6 (22)	7 (21)
Grade 3–4	1 (4)	0 (0)
Colitis	7 (26)	5 (15)
Grade 3–4	4 (15)	1 (3)
Endocrinopathy *	5 (19)	6 (18)
Grade 3–4	2 (7)	3 (9)
Hepatitis	6 (22)	2 (6)
Grade 3–4	4 (15)	0 (0)
Arthritis/arthralgia	3 (11)	2 (6)
Grade 3–4	0 (0)	0 (0)
Death **	2 (7)	0 (0)

Abbreviations: NIVO1 + IPI3, nivolumab 1 mg/kg + ipilimumab 3 mg/kg; NIVO3 + IPI1, nivolumab 3 mg/kg + ipilimumab 1 mg/kg; AE, adverse event. * Endocrinopathy includes thyroiditis, adrenal insufficiency and hypophysitis. ** Two fulminant myocarditis cases.